false 0001718500 0001718500 2024-01-04 2024-01-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 4, 2024

 

 

 

REVIV3 PROCARE COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38112   43-1985966

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

         
901 Fremont Avenue, Unit 158, Alhambra, CA   91803
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 638-8883

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
None N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On January 4, 2024, Reviv3 Procare Company (the “Company”) issued a press release announcing its consolidated financial results for the three months ended November 30, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

 

Item 9.01Financial Statements and Exhibits.

 

(d)       Exhibits

 

Exhibit No.   Description

99.1

  Earnings Press Release of Reviv3 Procare Company, dated January 4, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

-1-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REVIV3 PROCARE COMPANY
   
Date: January 4, 2024

/s/ Jeff Toghraie

  Name: Jeff Toghraie
  Title: Chief Executive Officer

-2-

REVIV3 Procare Company Reports Record Second Quarter Fiscal Year 2024 Financial Results

  • Net Sales (revenue) increased 25.1% to a record $8.4 million for the second quarter ended November 30, 2023, as compared to the prior year period.
  • Gross Profit (as a percentage of Net Sales) was 74.3% as compared to 74.9% for the prior year period.
  • Operating expenses as a percentage of Net Sales was 59.3% as compared to 60.2% for the prior year period.
  • Net Income increased 40.1% to a record $1,018,075 as compared to $726,900 for the prior year period.

LOS ANGELES, January 4, 2024 (GLOBE NEWSWIRE) -- Reviv3 Procare Company (“Reviv3,” “we,” “us,” “our,” or the “Company”) (OTCQB: RVIV), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the second quarter ended November 30, 2023.

 

“We delivered another strong quarter, growing our net sales by approximately twenty-five percent and net income by approximately forty percent as compared to the second quarter of fiscal 2022. This quarter marks our sixth consecutive profitable quarter, which we believe is reflective of our continued focus on profitability while maintaining aggressive growth through market expansion and product innovation,” remarked Jeff Toghraie, CEO.

 

 

 

Financial Tables

 

REVIV3 PROCARE COMPANY AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS 

       
   November 30, 2023  May 31, 2023
    (Unaudited)      
           
ASSETS          
CURRENT ASSETS:          
 Cash  $5,962,431   $4,832,682 
 Accounts receivable, net   953,315    417,016 
 Inventory, net   2,352,215    1,311,864 
 Prepaid expenses and other current assets   1,068,767    801,360 
           
 Total Current Assets   10,336,728    7,362,922 
           
OTHER ASSETS:          
 Property and equipment, net   211,036    157,463 
 Intangible assets, net   343,924    382,674 
 Right of use asset   69,911    101,845 
 Other assets   12,195    12,195 
 Goodwill   2,152,215    2,152,215 
           
 Total Other Assets   2,789,281    2,806,392 
           
TOTAL ASSETS  $13,126,009   $10,169,314 
           
 LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
 Accounts payable  $1,922,159   $908,606 
 Customer deposits   100,889    183,688 
 Equipment payable, current   550    2,200 
 Contract liabilities, current   1,050,420    827,106 
 Notes payable, current   3,270    172,588 
 Due to related party   132,860    158,072 
 Lease liability, current   71,374    65,824 
 Income tax liability   661,295    230,913 
 Other current liabilities   534,067    305,664 
           
 Total Current Liabilities   4,476,884    2,854,661 
           
LONG TERM LIABILITIES:          
 Notes payable, long term   144,661    —   
 Lease liability, long term   —      36,752 
 Contract liabilities, long term   557,763    605,942 
           
 Total Long Term Liabilities   702,424    642,694 
           
Total Liabilities   5,179,308    3,497,355 
           
 Commitments and contingencies (see Note 11)   —      —   
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 shares issued and outstanding as of November 30, 2023 and May 31, 2023, respectively   25,000    25,000 
Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 shares issued, and outstanding as of November 30, 2023 and May 31, 2023   11,708    11,708 
Additional paid-in capital   10,204,458    10,102,243 
Accumulated deficit   (2,294,465)   (3,466,992)
           
Total Stockholders’ Equity   7,946,701    6,671,959 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $13,126,009   $10,169,314 

 

 

 

 

 

REVIV3 PROCARE COMPANY AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   For the Three Months Ended  For the Six Months Ended
   November 30,  November 30,
   2023  2022  2023  2022
             
Sales, net  $8,421,677   $6,731,999   $14,527,946   $10,969,357 
                     
Cost of sales   2,163,738    1,692,965    3,622,441    2,647,669 
                     
Gross profit   6,257,939    5,039,034    10,905,505    8,321,688 
                     
OPERATING EXPENSES:                    
 Marketing and selling expenses   3,672,780    3,098,898    6,879,621    5,076,874 
 Compensation and related taxes   204,646    509,339    484,635    790,027 
 Professional and consulting expenses   491,328    213,205    918,103    679,655 
 General and administrative   625,273    232,597    1,185,477    590,736 
                     
 Total Operating Expenses   4,994,027    4,054,039    9,467,836    7,137,292 
                     
INCOME FROM OPERATIONS   1,263,912    984,995    1,437,669    1,184,396 
                     
OTHER INCOME (EXPENSE):                    
 Gain on settlement   79,182    —      79,182    50,500 
 Other income   3,189    —      13,024    —   
 Interest income   37,825    4,704    76,318    6,541 
 Interest expense and other finance charges   (1,640)   (1,755)   (3,284)   (3,213)
                     
Other Income (Expense), Net   118,556    2,949    165,240    53,828 
                     
INCOME BEFORE PROVISION FOR INCOME TAXES   1,382,468    987,944    1,602,909    1,238,224 
                     
Provision for income taxes   364,393    261,044    430,382    335,797 
                     
NET INCOME  $1,018,075   $726,900   $1,172,527   $902,427 
                     
NET INCOME PER COMMON SHARE:                    
 Basic  $0.01   $0.01   $0.01   $0.01 
 Diluted  $0.00   $0.00   $0.00   $0.00 
                     
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                    
 Basic   117,076,949    115,226,893    117,076,949    108,779,476 
 Diluted   372,451,949    368,993,486    372,451,949    341,429,203 

 

 

 

 

 

REVIV3 PROCARE COMPANY AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED NOVEMBER 30, 2023 AND 2022

(UNAUDITED)

 

For the six months ended November 30, 2023
      Common Stock  Additional     Total
   Preferred Stock  Issued  Paid-in  Accumulated  Stockholders’
   Shares  Amount  Shares  Amount  Capital  Deficit  Equity
Balance, May 31, 2023   250,000,000   $25,000    117,076,949   $11,708   $10,102,243   $(3,466,992)  $6,671,959 
                                    
Stock options expense   —      —      —      —      102,215    —      102,215 
                                    
Net income for the six months ended November 30, 2023   —      —      —      —      —      1,172,527    1,172,527 
                                    
Balance, November 30, 2023   250,000,000   $25,000    117,076,949   $11,708   $10,204,458   $(2,294,465)  $7,946,701 

 

 

For the three months ended November 30, 2023 

         Common Stock  Additional     Total
   Preferred Stock  Issued  Paid-in  Accumulated  Stockholders’
   Shares  Amount  Shares  Amount  Capital  Deficit  Equity
Balance, August 31, 2023   250,000,000   $25,000    117,076,949   $11,708   $10,153,350   $(3,312,540)  $6,877,518 
                                    
Stock options expense   —      —      —      —      51,108    —      51,108 
                                    
Net income for the three months ended November 30, 2023   —      —      —      —      —      1,018,075    1,018,075 
                                    
Balance, November 30, 2023   250,000,000   $25,000    117,076,949   $11,708   $10,204,458   $(2,294,465)  $7,946,701 

 

 

For the six months ended November 30, 2022

         Common Stock  Additional     Total
   Preferred Stock  Issued  Paid-in  Accumulated  Stockholders’
   Shares  Amount  Shares  Amount  Capital  Deficit  Equity
Balance, May 31, 2022   —     $—      41,945,881   $4,195   $5,472,084   $(5,291,567)  $184,712 
                                    
Shares issued for acquisition of business   250,000,000    25,000    73,183,893    7,318    3,975,162    —      4,007,480 
                                    
Stock options expense   —      —      —      —      124,145    —      124,145 
                                    
Shares to be issued for cash   —      —      1,426,391    143    327,907    —      328,050 
                                    
Net income for the six months ended November 30, 2022   —      —      —      —      —      902,427    902,427 
                                    
Balance, November 30, 2022   250,000,000   $25,000    116,556,165   $11,656   $9,899,298   $(4,389,140)  $5,546,814 

 

 

For the three months ended November 30, 2022

         Common Stock  Additional     Total
   Preferred Stock  Issued  Paid-in  Accumulated  Stockholders’
   Shares  Amount  Shares  Amount  Capital  Deficit  Equity
Balance, August 31, 2022   250,000,000   $25,000    115,129,774   $11,513   $9,544,529   $(5,116,040)  $4,465,002 
                                    
Stock options expense   —      —      —      —      26,862    —      26,862 
                                    
Shares to be issued for cash   —      —      1,426,391    143    327,907    —      328,050 
                                    
Net income for the three months ended November 30, 2022   —      —      —      —      —      726,900    726,900 
                                    
Balance, November 30, 2022   250,000,000   $25,000    116,556,165   $11,656   $9,899,298   $(4,389,140)  $5,546,814 

 

 

 

 

REVIV3 PROCARE COMPANY AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   For the Six Months Ended
   November 30,
   2023  2022
       
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income  $1,172,527   $902,427 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   56,022    43,015 
Bad debts   64,327    105,975 
Deposit used in rent        8,385 
Stock based compensation   102,215    124,145 
Gain on settlement   (79,182)   (50,500)
Amortization of prepaid expense   —      3,159 
Change in operating assets and liabilities:          
Accounts receivable   (600,626)   (563,594)
Inventory   (1,040,351)   (447,830)
Prepaid expenses and other current assets   (267,407)   (243,010)
Deposits   —      (12,195)
Accounts payable and accrued expenses   1,092,735    651,365 
Other current liabilities   576,718    1,327,096 
Contract liabilities   175,135    347,757 
           
NET CASH PROVIDED BY OPERATING ACTIVITIES   1,252,113    2,196,195 
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Cash acquired on business acquisition   —      1,066,414 
Purchase of property and equipment   (70,845)   (54,400)
           
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES   (70,845)   1,012,014 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Cash raised for common stock to be issued   —      328,050 
Repayment of equipment financing   (1,650)   (1,750)
Repayment of note payable   (24,657)   (1,462)
Advances (payments) from a related party   (25,212)   111,392 
           
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES   (51,519)   436,230 
           
NET INCREASE IN CASH   1,129,749    3,644,439 
           
CASH - Beginning of period   4,832,682    373,731 
           
CASH - End of period  $5,962,431   $4,018,170 
    —        
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
Interest  $3,284   $250 
Income taxes  $—     $—   
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Stock issued for asset purchase agreement  $—     $4,007,480 
Tangible assets (excluding cash) acquired in business combination  $—     $1,740,729 
Intangible assets acquired in business combination  $—     $456,945 
Goodwill acquired in business combination  $—     $2,152,215 
Liabilities assumed in business combination  $—     $1,408,823 

 

 

 

About Reviv3

 

Reviv3 Procare Company (OTCQB: RVIV) is an emerging global e-commerce consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL® brand and premium hair and skincare products under its in-house Reviv3 Procare brand - selling products in the United States, Canada, the European Union and throughout Asia. To learn more, please visit the Company’s website at www.reviv3.com and, for the AXIL® brand, visit www.goaxil.com.

 

Forward-Looking Statements

 

This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as ”believe,” “focus,” and “growth,” among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management’s beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management’s control and may cause Reviv3’s results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3’s ability to grow net sales as anticipated and perform in accordance with guidance; (ii) Reviv3’s ability to generate sufficient revenue to support Reviv3’s operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives, including continued integration of the AXIL® brand; (iv) Reviv3’s ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of Reviv3’s customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3’s product costs and other costs of doing business, and reduce Reviv3’s earnings; and (vii) the impact of unstable market and general economic conditions on Reviv3’s business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict, the Israel-Hamas conflict and the ongoing impact of worldwide pandemics and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

 

Investor Relations:

Reviv3 Investor Relations Team

(888) 638-8883

investors@reviv3.com

 

 

 

 

 

 

v3.23.4
Cover
Jan. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 04, 2024
Entity File Number 001-38112
Entity Registrant Name REVIV3 PROCARE COMPANY
Entity Central Index Key 0001718500
Entity Tax Identification Number 43-1985966
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 901 Fremont Avenue
Entity Address, Address Line Two Unit 158
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91803
City Area Code (888)
Local Phone Number 638-8883
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false

Reviv3 Procare (QB) (USOTC:RVIV)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Reviv3 Procare (QB) Charts.
Reviv3 Procare (QB) (USOTC:RVIV)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Reviv3 Procare (QB) Charts.